Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women.

Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD.

BMC Womens Health. 2010 Sep 1;10:27. doi: 10.1186/1472-6874-10-27.

2.

Human papillomavirus vaccine acceptability among a national sample of adult women in the USA.

Stupiansky NW, Rosenthal SL, Wiehe SE, Zimet GD.

Sex Health. 2010 Sep;7(3):304-9. doi: 10.1071/SH09127.

PMID:
20719219
3.

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9. Erratum in: MMWR Morb Mortal Wkly Rep. 2010 Sep 17;59(36):1184.

4.

Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation.

Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD.

Vaccine. 2011 Jan 29;29(5):890-5. doi: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.

PMID:
20056186
5.

Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey.

Caskey R, Lindau ST, Alexander GC.

J Adolesc Health. 2009 Nov;45(5):453-62. doi: 10.1016/j.jadohealth.2009.04.021. Epub 2009 Jun 24.

PMID:
19837351
6.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
7.

Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination.

Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, Glynn S, Kahn JA.

J Womens Health (Larchmt). 2009 Oct;18(10):1679-86. doi: 10.1089/jwh.2008.1329.

PMID:
19785564
8.

Parents' health beliefs and HPV vaccination of their adolescent daughters.

Reiter PL, Brewer NT, Gottlieb SL, McRee AL, Smith JS.

Soc Sci Med. 2009 Aug;69(3):475-80. doi: 10.1016/j.socscimed.2009.05.024. Epub 2009 Jun 18.

PMID:
19540642
9.

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.

PMID:
19493565
10.

The HPV vaccines--which to prefer?

Bornstein J.

Obstet Gynecol Surv. 2009 May;64(5):345-50. doi: 10.1097/OGX.0b013e31819f992e. Review.

PMID:
19386141
11.

One in four California adolescent girls have had human papillomavirus vaccination.

Grant D, Kravitz-Wirtz N, Breen N, Tiro JA, Tsui J.

Policy Brief UCLA Cent Health Policy Res. 2009 Feb;(PB2009-3):1-6. No abstract available.

12.

Literature review of human papillomavirus vaccine acceptability among women over 26 years.

Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL.

Vaccine. 2009 Mar 10;27(11):1668-73. doi: 10.1016/j.vaccine.2009.01.035. Epub 2009 Feb 3. Review.

PMID:
19195491
13.

Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern women.

Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS.

J Rural Health. 2009 Winter;25(1):93-7. doi: 10.1111/j.1748-0361.2009.00204.x.

PMID:
19166567
14.

Stage of adoption of the human papillomavirus vaccine among college women.

Allen JD, Mohllajee AP, Shelton RC, Othus MK, Fontenot HB, Hanna R.

Prev Med. 2009 May;48(5):420-5. doi: 10.1016/j.ypmed.2008.12.005. Epub 2008 Dec 24.

PMID:
19133288
15.

Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.

Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L.

Prev Med. 2009 May;48(5):426-31. doi: 10.1016/j.ypmed.2008.11.010. Epub 2008 Dec 6.

PMID:
19100762
16.

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G; HPV Study Group for Adult Women.

Vaccine. 2009 Jan 22;27(4):581-7. doi: 10.1016/j.vaccine.2008.10.088. Epub 2008 Nov 18.

PMID:
19022320
17.

Natural history and epidemiology of HPV infection and cervical cancer.

Castellsagué X.

Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7. doi: 10.1016/j.ygyno.2008.07.045. Review.

PMID:
18760711
18.

Intent to receive an HPV vaccine among university men and women and implications for vaccine administration.

Jones M, Cook R.

J Am Coll Health. 2008 Jul-Aug;57(1):23-32. doi: 10.3200/JACH.57.1.23-32.

PMID:
18682342
19.

Women's knowledge, attitudes, and intentions concerning Human Papillomavirus vaccination: findings of a waiting room survey of obstetrics-gynaecology outpatients.

Lenehan JG, Leonard KC, Nandra S, Isaacs CR, Mathew A, Fisher WA.

J Obstet Gynaecol Can. 2008 Jun;30(6):489-499. doi: 10.1016/S1701-2163(16)32864-X.

PMID:
18611300
20.

Human papillomavirus and vaccination.

Huang CM.

Mayo Clin Proc. 2008 Jun;83(6):701-6; quiz 706-7. doi: 10.4065/83.6.701. Review.

PMID:
18533087

Supplemental Content

Support Center